Report on recent treatment of Hodgkin' s lymphoma in the 54th ASH annual meeting
10.3760/cma.j.issn.1009-9921.2013.01.009
- VernacularTitle:霍奇金淋巴瘤治疗进展:第54届美国血液学会年会深度报道
- Author:
Zhijian ZOU
;
Wei XU
;
Jianyong LI
- Publication Type:Journal Article
- Keywords:
Lymphoma,Hodgkin;
Treament;
ASH annual meeting
- From:
Journal of Leukemia & Lymphoma
2013;22(1):21-24
- CountryChina
- Language:Chinese
-
Abstract:
Early stage Hodgkin' s lymphoma (HL) is highly curable with abbreviated chemotherapy plus involved-filed radiotherapy or chemotherapy alone,but the role of radiation remains the subject of debate and disagreement.The management of recurrent or refractory HL remains challenging with limited effective treatments except high dose therapy with autologous stem cell transplantation.Emerging new safe and effective drugs such as brentuximab vedotin might promisingly improve the outcome of these patients in the future.The interim positron emission tomography (PET-i) scan has important prognostic value in patients with early and advanced stage HL,especially PET scan after 2 cycles.However,the PET-i guided treatment decisions are not currently recommended outside clinical trials.
